Biodrugs

Papers
(The TQCC of Biodrugs is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review207
Is There Any Research Evidence Beyond Surveys and Opinion Polls on Automatic Substitution of Biological Medicines? A Systematic Review107
Lupus Nephritis: New and Emerging Biologic and Targeted Therapies92
Outer Membrane Vesicle Vaccine Platforms79
Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases74
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network65
Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries51
Investigational Agents in Development for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration48
Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies47
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study45
Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins41
Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians33
Enhancing the Response Rate to Recombinant Uricases in Patients with Gout31
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience31
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)30
Clinical Features and Drug Retention of TNF Inhibitors in Older Patients with Ankylosing Spondylitis: Results from the KOBIO Registry30
Evaluating Gene Therapy as a Potential Paradigm Shift in Treating Severe Hemophilia30
Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study29
Plant-Derived Human Vaccines: Recent Developments28
Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the Association27
Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial27
Treatment with Biologic Drugs in Pediatric Behçet’s Disease: A Comprehensive Analysis of the Published Data27
The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland27
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options26
Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis25
Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans24
Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment23
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects22
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond22
Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?21
Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy20
The Evolving Applications of Bispecific Antibodies: Reaping the Harvest of Early Sowing and Planting New Seeds19
Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar19
Unlocking the Power of Complement-Dependent Cytotoxicity: Engineering Strategies for the Development of Potent Therapeutic Antibodies for Cancer Treatments19
AAV-Based Strategies for Treatment of Retinal and Choroidal Vascular Diseases: Advances in Age-Related Macular Degeneration and Diabetic Retinopathy Therapies19
Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations18
Targeting the Inside of Cells with Biologicals: Chemicals as a Delivery Strategy17
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer17
Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One17
RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis17
Comparative Structure Activity Relationship Characterization of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab16
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome15
Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects15
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making15
Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active 14
Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?14
Correction to: Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study14
Acknowledgement to Referees14
A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study14
Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis14
Complement Inhibition in Kidney Transplantation: Where Are We Now?14
Correction: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy13
Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy13
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery12
Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome)12
Enzyme Engineering Strategies for the Bioenhancement of l-Asparaginase Used as a Biopharmaceutical12
Nano–Bio Interactions: Exploring the Biological Behavior and the Fate of Lipid-Based Gene Delivery Systems11
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor11
Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer11
Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions11
Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region11
0.10510015487671